-
AngII, Cx43, and M1 Macrophage Polarization
2026-10-02
The reference study identifies a connexin 43 (Cx43)/NF-κB p65 axis through which angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype. Its combined inhibitor, gene-expression, protein, cytokine, and flow-cytometry analyses provide a useful framework for testing Cx43-dependent inflammatory signaling while highlighting the limits of inferring hemichannel-specific mechanisms from pharmacology alone.
-
Disodium bicinchoninate in Endothelial Assays
2026-10-01
Disodium bicinchoninate provides an aqueous route for copper-based protein quantification and normalization in oxidative-stress studies, without relying on DMSO or ethanol. This workflow connects reliable lysate handling with the EZH2, inflammation, and autophagy findings reported in H2O2-challenged endothelial cells.
-
2',7'-Dichlorofluorescein diacetate for ROS Assays
2026-10-01
Use 2',7'-Dichlorofluorescein diacetate as a practical intracellular redox readout across microscopy, flow cytometry, and plate assays. Its value in pancreatic cancer nanocarrier research is greatest when general oxidative-stress fluorescence is paired with viability, localization, and pathway-specific validation.
-
SGI-1027 and Everolimus in Renal Cancer
2026-09-30
A 2024 Advanced Science study identifies SGI-1027 as a methuosis-inducing compound and shows that it cooperates with everolimus against renal cancer cells. The combination links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a mechanistic strategy for addressing everolimus resistance while supporting further validation in clinically relevant models.
-
GI 254023X: Selective ADAM10 Inhibitor Workflows
2026-09-30
GI 254023X enables focused interrogation of ADAM10 sheddase activity in Jurkat signaling and endothelial barrier models. Its combination of nanomolar biochemical potency, ADAM17 selectivity, and practical cell-assay guidance supports cleaner mechanistic experiments than broad metalloprotease inhibition.
-
Pronase E: Proteolysis for Mechanism-Aware Assays
2026-09-29
Pronase E is more than a broad protease mixture for routine digestion. This guide explains how to deploy it as a controlled sample-preparation enzyme alongside target-engagement, ferroptosis, and proteomic assays without confusing protein degradation with biological mechanism.
-
Predicting Netarsudil–siRNA Codelivery
2026-09-29
Slaughter and colleagues developed a quantitative workflow for predicting whether ionizable drugs can complex siRNA and function as active components of drug-containing nanoparticles. Netarsudil emerged as a high-performing candidate, enabling CTGF-targeting siRNA delivery in fibrotic human trabecular meshwork cells and linking nanoparticle formulation with cytoskeletal biology.
-
Kir2.1 Inhibition Limits PASMC Growth and Migration
2026-09-28
The study links Kir2.1 activity with pulmonary artery smooth muscle cell proliferation, migration, and pulmonary vascular remodeling using a rat model and cultured human cells. Pharmacological inhibition with ML133 reduced PDGF-BB-associated cellular responses and TGF-β1/SMAD2/3 signaling, identifying Kir2.1 as a candidate for further mechanistic investigation—not yet an established therapeutic target.
-
ARv7 and EPI-001 in Triple-Negative Breast Cancer
2026-09-27
This study combines patient-tissue and TCGA analyses with MDA-MB-231 experiments to examine AR and ARv7 as prognostic features and therapeutic targets in triple-negative breast cancer. Its findings associate ARv7 with adverse outcomes and show that Enzalutamide and EPI-001 alter migration- and EMT-related markers in vitro, supporting further mechanistic—not yet clinical—investigation.
-
Sorafenib Beyond the Kinase Panel
2026-09-26
Sorafenib is more than a kinase inhibitor to add to a screening panel: it is a research probe for connecting RAF-dependent tumor-cell signaling with VEGFR-linked angiogenesis. This article considers how to use BAY-43-9006 to build stronger, more translational experiments—and how emerging VEGFR-2 inhibitors can sharpen that strategy.
-
EZ Cap™ CPF1/Cas12a mRNA: Reading the Editing Window
2026-09-26
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) is a Cas12a-encoding research reagent for CRISPR genome editing. This article explains how to interpret editing as a time-dependent process shaped by target-site architecture, guide performance, and DNA repair—not simply nuclease delivery.
-
3-Deazaneplanocin A hydrochloride: DZNep Workflows
2026-09-25
Use DZNep to test how EZH2-associated repression and H3K27me3 relate to cell fate, proliferation, and apoptosis—while distinguishing broad chromatin perturbation from locus-specific restoration. This guide outlines practical dose-and-time workflows for AML and metabolic studies, plus cautious ways to interpret experiments in human pluripotent stem cells.
-
Thioguanine Workflows for Cancer and EV71 Assays
2026-09-25
Thioguanine supports distinct in-vitro oncology and EV71 research questions, with reported activity across cancer cell models and an EV71 assay in HT-29 cells. This workflow guide shows how to prepare the compound, choose complementary readouts, and avoid mistaking cytotoxicity or model-specific results for a universal mechanism.
-
mCherry mRNA for Nanoparticle Workflow Validation
2026-09-24
Use red fluorescent protein mRNA to track functional delivery, compare formulation conditions, and optimize reporter assays without confusing particle uptake with successful protein expression. EZ Cap™ mCherry mRNA (5mCTP, ψUTP) combines Cap 1, modified nucleotides, and a poly(A) tail for a practical fluorescent readout in cell-based workflows.
-
Anagliptin Relaxes Rabbit Aorta via Kv and SERCA
2026-09-24
A rabbit-aorta study reports that anagliptin relaxes phenylephrine-contracted vessels through mechanisms involving voltage-dependent potassium channels and the SERCA pump. Its inhibitor-based experiments distinguish these effects from several other potassium-channel classes, cyclic-nucleotide pathways, and endothelial signaling, while leaving direct molecular targets and clinical relevance unresolved.